Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

Ljungman P., de la Camara R., Perez-Bercoff L., Abecasis M., Nieto Campuzano J. B. , Jimena Cannata-Ortiz M., ...Daha Fazla

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, cilt.96, sa.8, ss.1231-1235, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 96 Konu: 8
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3324/haematol.2011.041913
  • Sayfa Sayıları: ss.1231-1235


During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective study was performed to collect data regarding risk factors and outcome of A/H1N1 in hematopoietic stem cell transplant recipients. Only verified pandemic A/H1N1 influenza strains were included: 286 patients were reported, 222 allogeneic and 64 autologous recipients. The median age was 38.3 years and the median time from transplant was 19.4 months. Oseltamivir was administered to 267 patients and 15 patients received zanamivir. One hundred and twenty-five patients (43.7%) were hospitalized. Ninety-three patients (32.5%) developed lower respiratory tract disease. In multivariate analysis, risk factors were age (OR 1.025; 1.01-1.04; P=0.002) and lymphopenia (OR 2.49; 1.33-4.67; P<0.001). Thirty-three patients (11.5%) required mechanical ventilation. Eighteen patients (6.3%) died from A/H1N1 infection or its complications. Neutropenia (P=0.03) and patient age (P=0.04) were significant risk factors for death. The 2009 A/H1N1 influenza pandemic caused severe complications in stem cell transplant recipients.